INTRODUCTION
Globally, enterococci cause approximately 10% of healthcareassociated bacteraemias, with a significant proportion of these being vancomycin-resistant Enterococcus faecium (VREfm) [1, 2] . VREfm bacteraemia has significant associated morbidity and mortality, particularly in haematology Abstract Introduction. The majority of vancomycin-resistant Enterococcus faecium (VREfm) in Australia is of the vanB genotype. An outbreak of vanA VREfm emerged in our haematology/oncology unit between November 2014 and May 2015. The first case of daptomycin non-susceptible E. faecium (DNSEfm) detected was a patient with vanA VREfm bacteraemia who showed clinical failure of daptomycin therapy, prompting microbiologic testing confirming daptomycin non-susceptibility.
Objectives. To describe the patient profiles, antibiotic susceptibility and genetic relatedness of vanA VREfm isolates in the outbreak.
Methods. Chart review of vanA VREfm colonized and infected patients was undertaken to describe the demographics, clinical features and outcomes of therapy. Whole genome sequencing of vanA VREfm isolates involved in the outbreak was conducted to assess clonality.
Results. In total, 29 samples from 24 patients tested positive for vanA VREfm (21 screening swabs and 8 clinical isolates). Five isolates were DNSEfm (four patients colonized, one patient with bacteraemia), with only one patient exposed to daptomycin previously. In silico multi-locus sequence typing of the isolates identified 25/26 as ST203, and 1/26 as ST796. Comparative genomic analysis revealed limited core genome diversity amongst the ST203 isolates, consistent with an outbreak of a single clone of vanA VREfm.
Conclusions.
Here we describe an outbreak of vanA VREfm in a haematology/oncology unit. Genomic analysis supports transmission of an ST203 vanA VRE clone within this unit. Daptomycin non-susceptibility in 5/24 patients left linezolid as the only treatment option. Daptomycin susceptibility cannot be assumed in vanA VREfm isolates and confirmatory testing is recommended.
and oncology patients [3, 4] . Australian data have shown that enterococci have overtaken Staphylococcus aureus as the most common cause of central-line-associated blood-stream infections [5] .
VREfm emerged in Europe and the USA in the 1980s, with the first clinical case in Australia reported in 1994 [6] . The incidence of VREfm in Australia remained low until outbreaks of vanB VREfm occurred in the mid-2000s [7, 8] , when it subsequently became endemic. The incidence of VREfm colonization in hospitalized patients in Australia is high (18% in a recent study [9] ) relative to the rest of the world. The reason for this is unknown. Many Australian hospitals, including our own centre, actively screen for VREfm in haematologyoncology and transplant units.
The predominant type of VRE is vanA VREfm in most regions of the world such as the USA [10] , whilst the great majority of the VREfm in Australian hospitals has been of vanB genotype [11] . Until recently, there was little evidence of vanA VREfm in Australia from available surveillance data [12] . However, the molecular epidemiology of VREfm in Australia is changing, with a significant increase in the incidence of vanA VREfm recently noted; of the 203 invasive VREfm isolates captured in the 2016 Australian Enterococcal Sepsis Outcome Program, the vanB and vanA genes were identified in 115 (56.6%) and 90 (44.3%) isolates, respectively [13] . Prior to 2015, vanA VREfm was very rare in our centre while vanB VRE was endemic.
The first case of daptomycin non-susceptible Enterococcus faecium (DNSEfm) was reported by a USA group in 2005 [14] . There has only been one recent report of DNSEfm in Australia [15] and DNSEfm has been uncommonly reported internationally [16] [17] [18] [19] , with the majority reported in the USA. In a study of antibiotic resistance across 19 USA hospitals between 2007 and 2010, 3 .9% and 2% of all E. faecium clinical and blood-stream isolates, respectively, were DNSEfm [10] . There have been case reports in Germany, Spain and Switzerland in recent years [20] [21] [22] [23] , suggesting that DNSEfm may be emerging globally.
Our study aimed to describe the emergence of vanA VREfm in our haematology/oncology and bone marrow transplant units and in particular, the discovery of DNSEfm among this group. Whole genome sequencing (WGS) was performed to explore the relatedness of isolates in an attempt to better understand the emergence.
The index DNSEfm case
A 60-year-old Australian-born woman with a new diagnosis of acute myeloid leukemia (AML) was admitted for induction chemotherapy. During her initial admission she was found to be colonized with vanA VREfm on a surveillance rectal swab. Her postinduction bone marrow aspirate showed refractory AML and she was readmitted for reinduction chemotherapy. The patient had one brief episode of neutropenic fever on day 3 and received 3 days of piperacillin-tazobactam and daptomycin empirically at suboptimal dosing due to a prescribing error (3 mg kg −1 IV daily). A second episode of neutropenic fever occurred on day 17. Blood cultures revealed E. faecium (vanA VREfm confirmed by PCR). Daptomycin at 10 mg kg −1 IV daily was recommenced and the Hickman line removed. Bacteraemia persisted despite 5 days of daptomycin at 10 mg kg −1 daily. Daptomycin susceptibility testing was performed by E-test, which revealed a MIC of 12 µg ml −1 , considered daptomycin non-susceptible (CLSI 2015, version M100-S25). Linezolid was commenced with rapid defervescence and clearance of blood cultures. The patient was discharged home after count recovery and was treated with 2 weeks of linezolid in total without bacteremic relapse.
METHODS Setting
The Royal Melbourne Hospital is a university-affiliated tertiary referral hospital in Melbourne, Australia with haematology/oncology and bone marrow transplant (BMT) units, which at the time of the outbreak incorporated a total of 28 inpatient beds. The haematology/oncology ward had eight single rooms and four three-bed rooms with a case-mix of non-malignant haematology, malignant haematology with induction and consolidation chemotherapy delivery and oncology patients receiving chemotherapy. All eight rooms on the BMT unit were single rooms reserved for patients undergoing or post bone marrow transplantation. Patients on these wards are routinely screened weekly for VRE using rectal swabs. VREfm colonized patients were managed in contact precautions (gowns and gloves) in single rooms where possible with dedicated toilet or commode. The haematology/ BMT unit has since been relocated with more inpatient beds and all single rooms. 
Case ascertainment and data collection
Prior to the outbreak, weekly VRE rectal screening swabs were performed on all patients in the haematology/oncology and BMT wards, however, vanA/B gene testing by PCR was not routine and clinical isolates were deemed to be vanB if phenotypically susceptible to teicoplanin and resistant to vancomycin. During the observation period, vanA/B gene testing by PCR was performed on all VRE phenotype isolates. Those patients who tested positive for vanA VREfm on screening swab alone were labelled as 'colonized' . Patients who had vanA VREfm detected on clinical specimens (e.g. urine or blood cultures) collected based on clinical suspicion of infection were considered to have vanA VREfm 'infection' for the purposes of this report. Retrospective chart review with data collected onto a standardized case report form was performed to describe the demographics, clinical features and outcomes of infection or colonization. Days in hospital were defined as inpatient bed-days, and did not include day ward admission.
Microbiology
Surveillance specimens were inoculated onto chromID VRE agar plates (Biomerieux, Marcy L'Etoile, France). Clinical isolates were identified to species level using matrixassisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF) (Bruker). All clinical and screening isolates were confirmed as vanA or vanB VREfm by PCR using Xpert vanA/vanB (Cepheid, Sunnyvale, USA). Antimicrobial susceptibilities for teicoplanin, linezolid and vancomycin were performed using Vitek 2 (Biomerieux), with interpretation according to Clinical and Laboratory Standards Institute guidelines (CLSI 2015, version M100-S25). Prior to the outbreak, daptomycin susceptibility testing was not performed as a routine. Daptomycin susceptibility testing was performed on Mueller Hinton agar (Oxoid, ThermoFisher Scientific, Australia) via E-test (Biomerieux), which was introduced on detection of the outbreak and performed on all vanA VREfm samples, with MIC ≤4 µg ml −1 labelled as susceptible, and all above this cut-off as non-susceptible (CLSI 2015, version M100-S25).
Whole genome sequencing
To assess the clonality of the vanA VREfm, 26 of 29 isolates were referred to the Microbiological Diagnostic Unit Public Health Laboratory for whole genome sequencing (WGS). Genomic DNA was extracted with the JANUS Automated Workstation using the Chemagic Viral DNA/RNA kit (PerkinElmer). Unique dual indexed libraries were prepared using the Nextera XT DNA sample prep kit (Illumina). Libraries were sequenced on the Illumina NextSeq 500 with 150-cycle paired end chemistry as described by the manufacturer's protocols.
Bioinformatic analysis
Short read sequence data was de novo assembled using Unicycler v0.40 [24] , run under a conservative assembly mode and excluding contigs less than 200 bp in length, and annotated using prokka v1.12 [25] . In silico multi-locus sequence typing (MLST) was performed using mlst v2.10-dev (http:// github. com/ tseemann/ mlst). As 25 of 26 isolates were classified as ST203, the sequence dataset was supplemented with the WGS data for all ST203 vanA VREfm isolates (n=5) recovered from the same institution during a VREfm survey performed between 10 November and 9 December 2015 [26] . A high-quality ST203 vanA VREfm reference genome (AUSMDU00004024, genome accession SAMN08628409) was also generated for this survey and has been used here as the reference genome for all mapping-based analyses (all data from this survey is available under project accession PRJNA433676). A full list of the isolates used in this study is provided in Table S1 (available in the online version of this article). All sequence data generated in this study has been deposited in the European Nucleotide Archive under project accession PRJEB23767.
The short read sequence data for all isolates was mapped to reference AUSMDU00004024 using snippy v2.3.2 (http:// github. com/ tseemann/ snippy), with a minimum coverage of ten reads and a base call stringency of 90 %. The core genome was defined as a site represented in each and every isolate in a given comparison. Maximum likelihood phylogenetic trees of all isolates (n=32, Fig. S1a ) and all ST203 vanA VREfm (n=30, Fig. S1b ), constructed from core genome single nucleotide polymorphisms (SNPs), were generated using PhyML v3.3 [27] . These were run under a HKY85 model of nucleotide substitution with 1000 bootstrap replicates. As the outbreak isolates were extremely clonal, core genome SNP diversity has been displayed in a minimum spanning network (Fig. 1) . This was generated in SplitsTree4 v4.14.6 [28] , using the minimum spanning network for distances, with 1000 spring embedder iterations and collapsing all identical nodes. The core genome SNPs used in this analysis are provided in Table S2 .
RESULTS

Outbreak description and patient outcomes
Between 16 November 2014 and 17 May 2015, 29 samples from 24 patients tested positive for vanA VREfm, including Fig. 1 . Minimum spanning network illustrating the genetic diversity amongst the outbreak isolates (n=26), constructed from core genome single nucleotide polymorphisms (SNPs). Pairwise SNP distance between isolates is indicated on each branch. The size of circles reflects the number of isolates with that genotype, and the colour indicates the phenotypic daptomycin susceptibility. Amongst the large cluster (n=17), a single isolate had a daptomycin MIC=6 µg ml −1 , which is not shown. The asterisk denotes the index case as described in the text. 21 screening swabs from 21 patients, and 8 clinical isolates from 8 patients. The demographics of patients involved in the outbreak are summarized in Table 1 . Of the clinical isolates, three were from blood cultures, three from urine cultures, one rectal biopsy and one infected haemorrhoid biopsy. Two out of eight patients with vanA VREfm infection died as a result of the pathogen, both with blood-stream infection.
Cleaning frequency was increased during the outbreak, which entailed a three-step clean (detergent, bleach and water rinse) for all daily and discharge cleans and twice daily cleaning of bathrooms in the implicated ward. Increased resources were also provided to increase the number of cleaners for the outbreak ward. Patients who developed neutropenic fever were given empiric piperacillin-tazobactam as first line empiric therapy. During the vanA VREfm outbreak, addition of daptomycin was recommended if the patient had either (1) known colonization with vanA VREfm and had signs of sepsis or (2) not known to be colonized with vanA VREfm but in septic shock.
Antimicrobial susceptibility
Five isolates from five patients tested non-susceptible to daptomycin (17 % DNSEfm, n=29 tested). Of these five patients, only one had a clinical infection; manifesting as persistent bacteraemia despite daptomycin therapy (see the index DNSEfm case). This patient had been exposed to daptomycin prior to DNSEfm isolation. The initial vanA VREfm isolated from the patient's rectal screening swab during induction was daptomycin susceptible (MIC 4 µg ml −1 ), and the subsequent blood culture isolate during reinduction was daptomycin non-susceptible (MIC 12 µg ml −1 ). The other patients colonized with DNSEfm had no prior exposure to daptomycin. All isolates tested (n=29) were susceptible to linezolid.
Comparative genomics
Of the 29 isolates recovered during the outbreak period, 26 were referred for WGS. In silico MLST identified 25/26 isolates as being ST203, with the single remaining isolate being ST796. To provide local context, all ST203 VREfm isolates (four vanA VREfm and one vanB VREfm) recovered from the same institution during a state-wide VREfm snapshot survey (conducted 6 months following the outbreak) were also included. The complete genome of a contemporary Australian vanA VREfm also recovered from the same statewide survey, has been used as the reference for all mappingbased analyses. A maximum likelihood phylogenetic tree of all isolates (n=32), and all ST203 vanA VRE (n=30) is provided in Fig. S1 . Both trees illustrate extremely limited core genome SNP diversity amongst the 25 ST203 isolates recovered during the outbreak period. One of the four ST203 vanA VREfm from the VREfm survey (AUSMDU00004160) also grouped amongst the outbreak isolates, and was phenotypically DNSEfm.
Core genome SNP diversity amongst the outbreak clone (n=26) is illustrated in Fig. 1 , in a minimum spanning network. Of the outbreak isolates, 17 (daptomycin MICs 3-6 µg ml −1 ) could not be differentiated at a core genome level. The remaining nine isolates (including four DNSEfm with MICs of 12 µg ml −1 ) differed from this main cluster by 1-6 SNPs, with a maximum pairwise SNP distance of 8 between any two isolates.
DISCUSSION
VanB VREfm has been the dominant VRE in Australia [11] , with only a small proportion being vanA. In this immunocompromised patient group, we observed the emergence of colonization and clinical infection with vanA VREfm. This has not been widely reported in the Australian setting before, although recent surveillance reports suggest a rapid increase in the proportion of VREfm being vanA [12, 26] . To our knowledge, this is the first report of a DNSEfm cluster in Australia, with only one other recent report of a DNSEfm Regarding the interpretation of the WGS findings, there were two mutations identified that were common to all DNSEfm with an MIC=12 mg l −1 , both located within predicted ABC transport genes (Table S2 ). However, both mutations were also identified in phenotypically susceptible isolates, specifically those found to be in phylogenetic proximity to the index isolate (Fig. 1) , subsequently their role in resistance is uncertain. Daptomycin resistance could be the result of mutations not captured in this analysis (e.g. movement of insertion sequences [29] ) or compensatory mutations in susceptible isolates may have masked the effect of a resistance-conferring SNP (Table S2) .
Although a definitive mechanism of resistance was not identified, WGS was crucial in establishing the close relatedness of vanA VREfm isolates in this patient group and the likely transmission of a single clone between patients. This is consistent with the lack of exposure of the colonized patients to daptomycin, with only one out of five patients exposed prior to identification of DNSEfm. Further, through the higher resolution afforded by WGS we were able to identify that the outbreak clone was still present in our institution 6 months after the outbreak, represented by a single isolate identified as part of a state-wide VREfm survey. This finding suggested that a reservoir may still exist for this multiresistant clone. Discriminating the outbreak clone from the other ST203 vanA VREfm identified in the survey because of their genetic similarity could not have been accomplished through other methods such as MLST and PFGE. As the cost is essentially equivalent to MLST and with turn-around times improving with increased demand for service, WGS is now a viable option to investigate outbreaks such as we have described. With the information provided by this technology, our infection prevention and control units were able to justify resource allocation to upscale infection control and antimicrobial stewardship involvement, both of which were necessary to curb the spread of vanA VREfm and emergence of DNSEfm.
The emergence of vanA VREfm and DNSEfm are particularly concerning for haematology/oncology patients who experience significant morbidity and mortality secondary to VRE infection [30] . Treatment options for DNSEfm are extremely limited, relying primarily on linezolid for serious infections, with the possible use of pristinamycin or tigecycline for less serious infections. There is concern among clinicians about the potential adverse effects of linezolid, in particular the risk of myelosuppression [31] and drug interactions particularly with antidepressant medication. Linezolid resistance has also been documented [10] . The emergence of spread of VREfm with phenotypic DNSEfm could have significant consequences, with increasing reliance on linezolid and potential emergence of pan-resistant VREfm isolates. Importantly, it appears that the index case of DNSEfm was colonized with a daptomycin-susceptible isolate initially, with suboptimal dosing of daptomycin during neutropenic fever (3 mg kg −1 IV daily) and subsequent isolation of DNSEfm in blood. Under-dosing of daptomycin may have led to the emergence of resistance. A recent study showed that daptomycin resistance can emerge on both an individual patient and population level with exposure to daptomycin, with 23.1 % of patients developing DNSEfm during their bacteraemia whilst on daptomycin (median dose of 6.4 mg kg −1 ), and the MIC to daptomycin rising overall during the study period [21] . We suggest ensuring optimization of daptomycin for systemic infection by susceptible isolates, with a recommended dose of 10-12 mg kg −1 intravenously daily [32] .
Our experience demonstrated the risk inherent in not testing for daptomycin susceptibility in those at high risk of morbidity and mortality from enterococcal infections such as the immunocompromised host. Prior to the outbreak, daptomycin susceptibility testing was not routinely performed due to the acknowledged poor reliability of automated testing techniques such as Vitek and MicroScan [33] . The more costly and time-consuming techniques required for reliable daptomycin susceptibility testing (E-test or broth microdilution [33] ) were thought unnecessary given the lack of reports of DNSEfm locally prior to the outbreak. This outbreak resulted in a modification of our practice and daptomycin susceptibility testing by E-test is routinely undertaken in haematology and oncology patients.
In conclusion, an outbreak of vanA VREfm occurred amongst haematology, oncology and BMT patients in an Australian hospital, with DNSEfm appearing to emerge during this time. This was only recognized when daptomycin susceptibility testing was specifically instituted. A single clone of ST203 vanA VREfm was the cause of the outbreak and appeared to spread rapidly throughout the unit. We recommend that hospitals remain vigilant for such outbreaks and the potential emergence of DNSEfm.
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